Document Preview Unavailable

First‐line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation‐positive non‐small cell lung cancer

Po‐Lan Su; Chian‐Wei Chen; Yi‐Lin Wu; Chien‐Chung Lin; Wu‐Chou Su.  Thoracic Cancer Vol. 12, Iss. 3,  (Feb 2021): 287-296.

You might have access to this document